Share

May 05, 2015; 84 (18) Article

Risk and protective factors for cognitive impairment in persons aged 85 years and older

Rosebud O. Roberts, Ruth H. Cha, Michelle M. Mielke, Yonas E. Geda, Bradley F. Boeve, Mary M. Machulda, David S. Knopman, Ronald C. Petersen
First published April 8, 2015, DOI: https://doi.org/10.1212/WNL.0000000000001537
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
845

Share

Article Information

vol. 84 no. 18 1854-1861
DOI: 
https://doi.org/10.1212/WNL.0000000000001537
PubMed: 
25854867
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received September 3, 2014
  • Accepted in final form December 18, 2014
  • First Published April 8, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Rosebud O. Roberts, MB, ChB, MS,
    2. Ruth H. Cha, MS,
    3. Michelle M. Mielke, PhD,
    4. Yonas E. Geda, MD, MSc,
    5. Bradley F. Boeve, MD,
    6. Mary M. Machulda, PhD, LP,
    7. David S. Knopman, MD and
    8. Ronald C. Petersen, MD, PhD
  1. Rosebud O. Roberts, MB, ChB, MS,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Alzheimer's Disease; Associate Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH U01 AG006786 [Coinvestigator] 2009-2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Mayo Clinic [coinvestigator], Driskill Foundation, and GHR Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ruth H. Cha, MS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Michelle M. Mielke, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I have received speaker honoraria from Eli Lilly and AbbVie.

    Editorial Boards:

    1. Alzheimer's and Dementia: The Journal of the Alzheimer Association, associate editor, 2012-present Journal of Alzheimer Disease, associate editor, 2012-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Eli Lilly and AbbVie

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Dr. Mielke was funded by the following NIH grants: U01 AG037526 U01 AG006786

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr. Mielke also received research support from the Walter S. and Lucienne B. Driskill Foundation which started in May 2012-present. Alzheimer drug discovery foundation. Role:PI. Date: 03/01/2013-present Michael J. Fox Foundation. Role: PI. Date: 01/01/2014-06/30/2015.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Yonas E. Geda, MD, MSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 2013 to present : Member, editorial board of International Psychogeriatrics.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health (NIH), K01 MH068531

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1-Harold Amos Medical Faculty Development Award (RWJ foundation). 2- European Union Regional Development Fund (CZ.1.05/1.1.00/02.0123)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Bradley F. Boeve, MD,
    6. Scientific Advisory Boards:

    1. Tau Consortium

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Grant support as an investigator in clinical trials funded by (1) Cephalon, Inc., 2009-2012, (2) Allon Therapeutics, Inc., 2010-2013; and (3) GE Healthcare, 2012-present.

    Research Support, Government Entities:

    1. National Institute on Aging [P50 AG016574 (2009-present), U01 AG006786 (2009-present), RO1 AG032306 (2010-present), RO1 AG041797 (2012-present) and UO1 AG045390 (2014- present)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Mangurian Foundation, 2011-present

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Mary M. Machulda, PhD, LP,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) National Institutes of Health; R01 DC 010367; Co- investigator 02/2010 - 01/2015 (2) Alzheimer's Association New Investigator Research Grant Co-Investigator 11/1/2012 - 10/31/2014 (3) National Institutes of Health; R01 DC 12519-01A1; Co- investigator 07/2013 - 06/2018 (4) Co-Investigator Core B - Clinical - Rochester in: Mayo Alzheimer's Disease Research Center. Funded by National Institute on Aging. (P50 AG 16574) 05/01/2014 - 04/30/2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. David S. Knopman, MD and
    8. Scientific Advisory Boards:

    1. Consultant Bluefield project (frontotemporal demantia); Lundbeck Pharmaceuticals (Sept 2013 ongoing); DIAN study DSMB (Sept 2013 ongoing).

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Lecture, University of Pennsylvania, January 2013 (2) Lecture, St Johns Hospital, Jackson Hole Wyoming June 2013 (3) Lecture, Amer Soc Neuroradiol, San Diego CA, May 2013 (4) Lectures, Alzheimer Conference, Seoul Korea, December 2014

    Editorial Boards:

    1. Neurology, Deputy Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Tau Rx clinical trial

    Research Support, Government Entities:

    1. NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer?s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Ronald C. Petersen, MD, PhD
    9. Scientific Advisory Boards:

    1. (1) Pfizer, Inc., Chair, Data Monitoring Committee; (2) Janssen Alzheimer Immunotherapy, Chair, Data Monitoring Committee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Mild Cognitive Impairment,Oxford University Press, 2003

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Roche Incorporated, (2) Merck, (3) Genentech

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-present) R01-AG011378 (Co-I) U01-AG024904 (Co-I) Non-financial disclosures: National Advisory Council on Aging, National Institute on Aging

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Divisions of Epidemiology (R.O.R., M.M. Mielke, Y.E.G., R.C.P.) and Biomedical Statistics and Informatics (R.H.C.), Department of Health Sciences Research, the Department of Neurology (R.O.R., B.F.B., D.S.K., R.C.P.), and the Department of Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; and the Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.
  1. Correspondence to Dr. Roberts: roberts.rosebud{at}mayo.edu
View Full Text

Article usage

Article usage: April 2015 to December 2021

AbstractFullPdfSource
Apr 20155347091Highwire
May 2015343051125Highwire
Jun 20156222325Highwire
Jul 20154441114Highwire
Aug 2015288610Highwire
Sep 201525676Highwire
Oct 20152531714Highwire
Nov 2015309710Highwire
Dec 201532823Highwire
Jan 201625525Highwire
Feb 201625010Highwire
Mar 201626217Highwire
Apr 201623033Highwire
May 201613812Highwire
May 20160179pmc
Jun 201619013Highwire
Jun 201601511pmc
Jul 201615323Highwire
Jul 201601211pmc
Aug 201616610Highwire
Aug 201601710pmc
Sep 201612541Highwire
Sep 201601716pmc
Oct 201612913Highwire
Oct 20160246pmc
Nov 201619712Highwire
Nov 20160166pmc
Dec 201611710Highwire
Dec 20160164pmc
Jan 201713023Highwire
Jan 201702010pmc
Feb 20178700Highwire
Feb 201704222pmc
Mar 201713513Highwire
Mar 20170176pmc
Apr 201720012Highwire
Apr 2017102122pmc
May 201749512Highwire
May 2017112422pmc
Jun 201730511Highwire
Jun 201791821pmc
Jul 201726700Highwire
Jul 201771515pmc
Aug 201721802Highwire
Aug 201782234pmc
Sep 201756323Highwire
Sep 201782331pmc
Oct 201713301Highwire
Oct 201762630pmc
Nov 201714813Highwire
Nov 201782833pmc
Dec 201710611Highwire
Jan 201830613Highwire
Feb 201813322Highwire
Mar 201817655Highwire
Apr 201849222Highwire
Apr 2018145064pmc
May 201836421Highwire
Jun 201824740Highwire
Jun 201853738pmc
Jul 201813811Highwire
Aug 201813512Highwire
Aug 201842222pmc
Sep 201812800Highwire
Oct 201814300Highwire
Nov 201816501Highwire
Dec 201816900Highwire
Jan 20198831Highwire
Feb 201911610Highwire
Mar 201913514Highwire
Apr 201915822Highwire
May 201911300Highwire
Jun 201910300Highwire
Jul 20199100Highwire
Aug 20197912Highwire
Sep 201913272Highwire
Oct 201915174Highwire
Nov 201912328Highwire
Dec 201911540Highwire
Jan 20209400Highwire
Feb 202012311Highwire
Mar 202031621Highwire
Apr 202089920Highwire
May 2020187712Highwire
Jun 202052210Highwire
Jul 202018400Highwire
Aug 202023100Highwire
Sep 202014511Highwire
Oct 202015102Highwire
Nov 202013932Highwire
Dec 202015210Highwire
Jan 202113412Highwire
Feb 202112820Highwire
Mar 202119710Highwire
Apr 202119610Highwire
May 202116931Highwire
Jun 202125000Highwire
Jul 202120720Highwire
Aug 202124600Highwire
Sep 202121300Highwire
Oct 202121010Highwire
Nov 202117411Highwire
Dec 202124331Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me